Anzeige
Mehr »
Login
Sonntag, 08.09.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Von Null auf 200 Millionen Dollar: Der unaufhaltsame Aufstieg von West Red Lake Gold
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 885823 | ISIN: US3755581036 | Ticker-Symbol: GIS
Tradegate
06.09.24
21:19 Uhr
70,97 Euro
-0,05
-0,07 %
1-Jahres-Chart
GILEAD SCIENCES INC Chart 1 Jahr
5-Tage-Chart
GILEAD SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
70,5470,8207.09.
70,9371,0706.09.
ACCESSWIRE
1.119 Leser
Artikel bewerten:
(2)

Gilead Sciences: Gilead Named One of America's Most JUST Companies by JUST Capital and CNBC

Company Also Ranked in Top 5 of Pharmaceuticals and Biotech Industry

FOSTER CITY, CA / ACCESSWIRE / February 20, 2024 / Gilead Sciences, Inc. (Nasdaq:GILD) announced the company has been named one of America's Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead's longstanding commitment to operate responsibly by prioritizing stakeholder engagement - including with the patients and communities the company serves, employees and shareholders - while working to create a healthier world for all people. Gilead was recognized on the top 100 list and ranked fifth in the Pharmaceuticals and Biotech industry.

"We have set ambitious goals that are helping to further embed corporate responsibility into our business and honor our commitment to create a better world for future generations," said Carmen Villar, Vice President, Public Affairs, Gilead Sciences. "We are proud to cultivate sustainable practices and an inclusive culture, while providing equitable opportunities for the communities we serve."

Gilead's Environmental, Social and Governance (ESG) strategy aims to position the company as the biotech employer and partner of choice while delivering shareholder value in a sustainable, responsible manner. Examples of Gilead's commitment to ESG include:

  • Expanding health equity around the world through programs that promote health system sustainability, strengthen infrastructure and provide education and financial support
  • Increasing access to medicines in low- and lower-middle income countries, including voluntary licensing for Gilead's HIV, hepatitis C and COVID-19 treatments
  • Creating an inclusive workplace that is representative of the diverse communities the company serves
  • Continuing to evolve the company's environmental sustainability program while progressing against ambitious goals focused on carbon, water, waste and packaging

Each year, JUST Capital collects and analyzes corporate data to evaluate the 1,000 largest public U.S. companies across 20 issues identified through comprehensive, ongoing public opinion research on Americans' attitudes toward responsible corporate behavior. For more about the JUST Capital rankings, visit: https://justcapital.com/reports/just-capital-and-cnbc-release-the-2024-rankings-of-americas-most-just-companies/

This recognition follows Gilead's recent announcement it was named to the Dow Jones Sustainability World Index for the third consecutive year, as well as the Dow Jones Sustainability North America Index, which highlight the most sustainable companies around the world based on a corporate sustainability assessment.

Details on Gilead's ESG commitments, goals and progress can be found in the company's Environmental Social Governance Impact Report, which is based on internationally recognized guidelines from the Global Reporting Initiative, the Sustainability Accounting Standards Board, the Taskforce on Climate Related Financial Disclosures and the United Nations Sustainable Development Goals. Learn more about Gilead's commitment to ESG at https://www.gilead.com/purpose/esg.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

Jacquie Ross, Investors
investor_relations@gilead.com

Meaghan Smith, Media
public_affairs@gilead.com

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:

Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Besser als NVIDIA! 3 KI- Favoriten mit riesigem Potenzial

Erleben Sie die KI-Revolution und sichern Sie sich gigantische Gewinne!

Nutzen Sie die einmalige Gelegenheit, die Ihnen die Künstliche Intelligenz bietet! Unser exklusiver Aktienreport enthüllt drei unglaublich aussichtsreiche KI-Aktien, die von der bahnbrechenden Entwicklung in diesem Sektor massiv profitieren können.

Warum sollten Sie dabei sein?

Weil eine Investition in KI-Unternehmen nicht nur Stabilität bringt, sondern auch das Potenzial hat, Ihr Depot explosionsartig wachsen zu lassen. Die letzten Jahre haben bewiesen: Wer auf KI setzt, kann außergewöhnliche Gewinne einfahren. Jetzt, nach einer kurzen Konsolidierungsphase, öffnen sich wieder sensationelle Einstiegsmöglichkeiten.

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche KI-Aktien das größte Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen die besten Investments im KI-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.